Cleared Traditional

K972627 - PACIFIC HEMOSTASIS IMMUNODEPLETED FACTOR V DEFICIENT PLASMA (THROMBOSDREEN BRAND) (100056)

K972627 is an FDA 510(k) clearance for PACIFIC HEMOSTASIS IMMUNODEPLETED FACTO..., manufactured by Pacific Hemostasis. The device is a Class 2 Hematology device with product code GJT cleared through the Traditional 510(k) pathway after a 30-day FDA review.

K972627 · Pacific Hemostasis · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1997
Decision
30d
Days
Class 2
Risk

K972627 is an FDA 510(k) clearance for the PACIFIC HEMOSTASIS IMMUNODEPLETED FACTOR V DEFICIENT PLASMA (THROMBOSDREEN BR.... Classified as Plasma, Coagulation Factor Deficient (product code GJT), Class II - Special Controls.

Submitted by Pacific Hemostasis (Huntersville, US). The FDA issued a Cleared decision on August 13, 1997 after a review of 30 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pacific Hemostasis devices

FDA 510(k) Submission Details - K972627

510(k) Number K972627 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 14, 1997
Decision Date August 13, 1997
Days to Decision 30 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
83d faster than avg
Panel avg: 113d · This submission: 30d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GJT Device Classification - Class 2, Special Controls

Product Code GJT Plasma, Coagulation Factor Deficient
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GJT Plasma, Coagulation Factor Deficient

All 74
Devices cleared under the same product code (GJT) and FDA review panel - the closest regulatory comparables to K972627.
CRYO CHECK FACTOR XI DEFICIENT PLASMA, MODEL FDP11-10 (1.OML) AND FDP11-15 (1.5ML)
K981173 · Precision Biologicals, Inc. · Jan 1999
CRYO CHECK FACTOR XII DEFICIENT PLASMA MODEL FDP12-10 (1.0ML) AND FDP12-15 (1.5ML)
K981174 · Precision Biologicals, Inc. · Jan 1999
COAGULATION FACTOR V DEFICIENT PLASMA
K981709 · Dade Behring, Inc. · Oct 1998
CRYO CHECK FACTOR V DEFICIENT PLASMA
K971223 · Precision Biologicals, Inc. · Jul 1997
CRYO CHECK FACTOR IX DEFICIENT PLASMA
K971226 · Precision Biologicals, Inc. · Jul 1997
CRYO CHECK FACTOR X DEFICIENT PLASMA
K971227 · Precision Biologicals, Inc. · Jul 1997